{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:35:25Z","timestamp":1789936525699,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ygyno.2013.12.031","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T00:45:52Z","timestamp":1388796352000},"page":"455-461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Inhibition of \u03b14\u03b21 integrin increases ovarian cancer response to carboplatin"],"prefix":"10.1016","volume":"132","author":[{"given":"Jennifer M.","family":"Scalici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Harrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill K.","family":"Slack-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.12.031_bb0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.humpath.2004.03.005","article-title":"Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives","volume":"35","author":"Bell","year":"2004","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0010","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1158\/0008-5472.CAN-08-2678","article-title":"Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis","volume":"69","author":"Slack-Davis","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0015","first-page":"336","article-title":"VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer","volume":"5","author":"Huang","year":"2013","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0020","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2967\/jnumed.112.117796","article-title":"Imaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancer","volume":"54","author":"Scalici","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","article-title":"Integrins as therapeutic targets","volume":"33","author":"Goodman","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428190009060320","article-title":"Integrin-mediated drug resistance in multiple myeloma","volume":"38","author":"Damiano","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0035","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis","volume":"104","author":"Mori","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1535-7163.91.4.1","article-title":"Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model","volume":"4","author":"Olson","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0045","first-page":"218","article-title":"Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo","volume":"21","author":"Schmidmaier","year":"2006","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1083\/jcb.114.3.557","article-title":"A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture","volume":"114","author":"Miyake","year":"1991","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0055","doi-asserted-by":"crossref","first-page":"14270","DOI":"10.1074\/jbc.270.24.14270","article-title":"Molecular mapping of functional antibody binding sites of alpha 4 integrin","volume":"270","author":"Schiffer","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/HAB-1997-8102","article-title":"Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis","volume":"8","author":"Leger","year":"1997","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0065","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1593\/neo.11138","article-title":"Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma","volume":"13","author":"Jazaeri","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0070","first-page":"996","article-title":"Vascular cell adhesion molecule-1 expressed by peritoneal mesothelium partly mediates the binding of activated human T lymphocytes","volume":"22","author":"Cannistra","year":"1994","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0075","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1084\/jem.176.4.1165","article-title":"Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells","volume":"176","author":"Jonjic","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fimmu.2011.00029","article-title":"IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer","volume":"2","author":"Hart","year":"2011","journal-title":"Front Immunol"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0085","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/0008-5472.CAN-06-4375","article-title":"Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice","volume":"67","author":"Robinson-Smith","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0090","first-page":"6449","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review","volume":"49","author":"Vaupel","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1071-5576(01)00122-8","article-title":"Composition of the extracellular matrix of the peritoneum","volume":"8","author":"Witz","year":"2001","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1006\/gyno.1995.1214","article-title":"Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer","volume":"58","author":"Cannistra","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0105","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0002-9440(10)65406-5","article-title":"CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells","volume":"154","author":"Lessan","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/gyno.1999.5388","article-title":"Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro","volume":"73","author":"Strobel","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","article-title":"Multicellular spheroids in ovarian cancer metastases: biology and pathology","volume":"113","author":"Shield","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0120","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","article-title":"Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?","volume":"67","author":"Warnke","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0125","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1158\/1078-0432.CCR-11-2904","article-title":"Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis","volume":"18","author":"Chen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0130","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nrd3266","article-title":"Integrins as therapeutic targets: lessons and opportunities","volume":"9","author":"Cox","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ygyno.2013.12.031_bb0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1474-4422(11)70299-X","article-title":"Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813013954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813013954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T12:46:35Z","timestamp":1688906795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813013954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0090825813013954"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.12.031","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of \u03b14\u03b21 integrin increases ovarian cancer response to carboplatin","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}